arrow_back Back to App

Generic Drugs: Faster Access, Lower Prices

This act aims to accelerate the market entry of more affordable generic drugs. As a result, citizens may gain quicker access to lower-priced medications, potentially reducing healthcare costs and increasing the availability of important treatments. These changes are intended to boost competition in the pharmaceutical market.
Key points
Allows faster approval of cheaper generic drugs, even if the first generic applicant has not yet received final approval.
Shortens the exclusivity period for the first generic drug if its approval is delayed, paving the way for other manufacturers.
May lead to lower drug prices and increased accessibility for patients.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_2853
Sponsor: Rep. Schrader, Kurt [D-OR-5]
Process start date: 2021-04-26
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

BLOCKING Act of 2021

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_2853.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-04-26.

What are the main provisions?

Key points include:

  • Allows faster approval of cheaper generic drugs, even if the first generic applicant has not yet received final approval.
  • Shortens the exclusivity period for the first generic drug if its approval is delayed, paving the way for other manufacturers.
  • May lead to lower drug prices and increased accessibility for patients.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Schrader, Kurt [D-OR-5].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-27.

CATEGORIES

Health Economy